Viewing nowZadium Tablet 25 mg (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

MFDS item code 202105532 · Approved 2021.07.23 · Insurance code 694004540
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. It can be used alone or in combination with other medications. Caution is advised for type 2 diabetes patients with cardiovascular disease if blood sugar is not adequately controlled; please refer to a healthcare professional for guidance. This medication is effective in improving blood glucose levels and helps in diabetes management.
The recommended dose of this drug is 10 mg once daily, either as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this drug is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this drug is administered concomitantly with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This drug may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this drug should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this drug well but have a persistent estimated glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This drug should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this drug in patients with end-stage renal disease (ESRD) or receiving dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this drug is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age or older. Initiation of this drug is not recommended in patients 85 years of age or older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).
This medication should not be used in patients who have had allergic reactions to the active ingredients or components. This medication is not suitable for patients with type 1 diabetes or diabetic ketoacidosis. It is contraindicated in patients with severely reduced kidney function, that is, with a glomerular filtration rate (GFR) below 30 mL/min/1.73 m², end-stage renal disease, or those undergoing dialysis. Since it contains lactose, it should not be used in patients with lactose intolerance, galactose intolerance, or genetic lactase deficiency. In patients with reduced kidney function, this medication should be used with caution, and treatment initiation should be avoided if the GFR is below 60 mL/min/1.73 m². If kidney function drops below 45 mL/min/1.73 m² during treatment, it is necessary to discontinue the medication. In patients with heart failure, especially those with mild to moderate cases, it should be used with caution, and it is not recommended for severe heart failure patients. There may be an increased risk of hypoglycemia when co-administered with insulin or sulfonylureas; thus, dose adjustments may be necessary. The most common side effect during use is hypoglycemia, particularly when used with insulin or sulfonylureas, so caution is warranted. Symptoms such as genital infections, urinary tract infections, increased urination, dehydration, and hypotension may occur, so consult a healthcare professional immediately if these symptoms arise. Rarely, serious metabolic disruptions such as ketoacidosis may occur, and immediate testing is required if symptoms like nausea, vomiting, abdominal pain, or respiratory distress appear. Use during pregnancy is not recommended, and the medication should be discontinued if pregnancy is confirmed. If breastfeeding, it is advisable to stop breastfeeding as this medication may be excreted in breast milk. Safety and effectiveness have not been established for children under 18 years of age. While no specific toxicity symptoms have been reported in case of overdose, appropriate treatment may be required depending on clinical conditions. This medication should be kept out of reach of children, and transferring to other containers should be avoided. There is a risk of hypoglycemia when driving or operating machinery, so caution is advised, especially when used with insulin or sulfonylureas. Regular kidney function tests should be performed during the course of treatment, and if symptoms of urinary tract or genital infections occur, notify a healthcare professional immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and moisture. The recommended storage temperature is between 1 to 30 degrees Celsius. Following these instructions helps safely maintain the effectiveness of the medication.
Pale yellow oval film-coated tablets
30 tablets/PTP [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.